ZLAB News and Press, Zai Lab Limited From 01/05/26

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026, at 3:00 p.m. PST / 6:00 p.m. EST. A live webcast of the presentation...

COBENFY is the first major advance in schizophrenia treatment in decades, offering a novel mechanism of action distinct from other therapies COBENFY has already been included in China’s national-level schizophrenia treatment guidelines, underscoring the urgent need for new therapeu...

- ZL-1503, a promising treatment for moderate-to-severe atopic dermatitis and other Type 2 helper T-cell (Th2)-driven diseases, strengthens Zai Lab’s growing global pipeline - ZL-1503 originated from Zai Lab’s in-house discovery and development engine Zai Lab Lim...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA): VYVGART® (efgartigimod alfa i...

2025-11-11 12:00:38 ET Top-Line Summary Analysts on Seeking Alpha, including myself , have been sanguine about the prospects of Zai Lab Limited ( ZLAB ), with various label expansions indicating to me that the company was becoming undervalued as they continue to build out th...

2025-11-07 08:17:00 ET More on Zai Lab Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Zoci and Outlines Next Steps in Clinical Development Transcript Zai Lab Limited (ZLAB) Discusses Updat...

2025-11-07 08:16:06 ET Zai Lab Limited (ZLAB) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Christine Chiou - Senior VP & Head of Investor Relations Ying Du - Founder, Chairperson & CEO Rafael Amado - President and Head of Global R...

2025-11-06 07:12:10 ET More on Zai Lab Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Zoci and Outlines Next Steps in Clinical Development Transcript Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Zoci and Outlines Next Steps in ...

– Zocilurtatug pelitecan (zoci, DLL3 ADC) (formerly ZL-1310) data presented at Triple Meeting in October continues to demonstrate first- and best-in-class potential, supporting the recent initiation of the global registrational study in 2L+ ES-SCLC – Advancing other high-p...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...